

# David L Paterson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2790292/publications.pdf>

Version: 2024-02-01

427  
papers

57,545  
citations

2091

103  
h-index

1446

226  
g-index

432  
all docs

432  
docs citations

432  
times ranked

44454  
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 318-327.	4.6	3,672
2	Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship. <i>Clinical Infectious Diseases</i> , 2007, 44, 159-177.	2.9	3,390
3	<i>Acinetobacter baumannii</i> : Emergence of a Successful Pathogen. <i>Clinical Microbiology Reviews</i> , 2008, 21, 538-582.	5.7	2,829
4	Extended-Spectrum $\beta$ -Lactamases: a Clinical Update. <i>Clinical Microbiology Reviews</i> , 2005, 18, 657-686.	5.7	2,767
5	Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection. <i>Annals of Internal Medicine</i> , 2000, 133, 21.	2.0	2,712
6	Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. <i>Lancet Infectious Diseases</i> , The, 2010, 10, 597-602.	4.6	2,485
7	Clinical epidemiology of the global expansion of <i>Klebsiella pneumoniae</i> carbapenemases. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 785-796.	4.6	1,328
8	Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. <i>Lancet Infectious Diseases</i> , The, 2006, 6, 589-601.	4.6	1,170
9	Critical Care Services and 2009 H1N1 Influenza in Australia and New Zealand. <i>New England Journal of Medicine</i> , 2009, 361, 1925-1934.	13.9	920
10	Antimicrobial Resistance in ESKAPE Pathogens. <i>Clinical Microbiology Reviews</i> , 2020, 33, .	5.7	898
11	Predictors of Mortality in <i>Staphylococcus aureus</i> Bacteremia. <i>Clinical Microbiology Reviews</i> , 2012, 25, 362-386.	5.7	701
12	<i>Escherichia coli</i> O25b-ST131: a pandemic, multiresistant, community-associated strain. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1-14.	1.3	629
13	Distribution of <i>Legionella</i> Species and Serogroups Isolated by Culture in Patients with Sporadic Community-acquired Legionellosis: An International Collaborative Survey. <i>Journal of Infectious Diseases</i> , 2002, 186, 127-128.	1.9	587
14	A Large Outbreak of <i>Clostridium difficile</i> Associated Disease with an Unexpected Proportion of Deaths and Colectomies at a Teaching Hospital Following Increased Fluoroquinolone Use. <i>Infection Control and Hospital Epidemiology</i> , 2005, 26, 273-280.	1.0	583
15	<i>Mycobacterium tuberculosis</i> Infection in Solid Organ Transplant Recipients: Impact and Implications for Management. <i>Clinical Infectious Diseases</i> , 1998, 27, 1266-1277.	2.9	557
16	Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E. coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infection and Ceftriaxone Resistance. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 984.	3.8	538
17	<i>Aspergillus</i> Infections in Transplant Recipients. <i>Clinical Microbiology Reviews</i> , 2005, 18, 44-69.	5.7	536
18	Resistance in Gram-Negative Bacteria: Enterobacteriaceae. <i>American Journal of Medicine</i> , 2006, 119, S20-S28.	0.6	517

#	ARTICLE	IF	CITATIONS
19	International Prospective Study of <i>Klebsiella pneumoniae</i> Bacteremia: Implications of Extended-Spectrum $\beta$ -Lactamase Production in Nosocomial Infections. <i>Annals of Internal Medicine</i> , 2004, 140, 26.	2.0	515
20	Antibiotic Therapy for <i>Klebsiella pneumoniae</i> Bacteremia: Implications of Production of Extended-Spectrum $\beta$ -Lactamases. <i>Clinical Infectious Diseases</i> , 2004, 39, 31-37.	2.9	512
21	Global dissemination of a multidrug resistant <i>Escherichia coli</i> clone. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 5694-5699.	3.3	498
22	Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. <i>Clinical Infectious Diseases</i> , 2018, 66, 163-171.	2.9	485
23	Community-Acquired <i>Klebsiella pneumoniae</i> Bacteremia: Global Differences in Clinical Patterns. <i>Emerging Infectious Diseases</i> , 2002, 8, 160-166.	2.0	476
24	Treatment Outcome of Bacteremia Due to KPC-Producing <i>Klebsiella pneumoniae</i> : Superiority of Combination Antimicrobial Regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2108-2113.	1.4	468
25	Analysis of Antibiotic Resistance Genes in Multidrug-Resistant <i>Acinetobacter</i> sp. Isolates from Military and Civilian Patients Treated at the Walter Reed Army Medical Center. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 4114-4123.	1.4	457
26	Setting and Revising Antibacterial Susceptibility Breakpoints. <i>Clinical Microbiology Reviews</i> , 2007, 20, 391-408.	5.7	455
27	Collateral Damage from Cephalosporin or Quinolone Antibiotic Therapy. <i>Clinical Infectious Diseases</i> , 2004, 38, S341-S345.	2.9	411
28	Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 226-240.	4.6	411
29	Multidrug-Resistant Bacteria in the Community. <i>Infectious Disease Clinics of North America</i> , 2016, 30, 377-390.	1.9	382
30	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 726-734.	4.6	367
31	Resistance in gram-negative bacteria: Enterobacteriaceae. <i>American Journal of Infection Control</i> , 2006, 34, S20-S28.	1.1	348
32	Risk Factors, Clinical Characteristics, and Outcome of <i>Nocardia</i> Infection in Organ Transplant Recipients: A Matched Case-Control Study. <i>Clinical Infectious Diseases</i> , 2007, 44, 1307-1314.	2.9	347
33	Invasive Aspergillosis in Transplant Recipients. <i>Medicine (United States)</i> , 1999, 78, 123-133.	0.4	328
34	Extended-Spectrum $\beta$ -Lactamases in <i>Klebsiella pneumoniae</i> Bloodstream Isolates from Seven Countries: Dominance and Widespread Prevalence of SHV- and CTX-M-Type $\beta$ -Lactamases. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 3554-3560.	1.4	325
35	The Effects of Hypoalbuminaemia on Optimizing Antibacterial Dosing in Critically Ill Patients. <i>Clinical Pharmacokinetics</i> , 2011, 50, 99-110.	1.6	325
36	Continuous Infusion of Beta-Lactam Antibiotics in Severe Sepsis: A Multicenter Double-Blind, Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2013, 56, 236-244.	2.9	317

#	ARTICLE	IF	CITATIONS
37	Augmented Renal Clearance. <i>Clinical Pharmacokinetics</i> , 2010, 49, 1-16.	1.6	313
38	Therapeutic drug monitoring of $\beta$ -lactams in critically ill patients: proof of concept. <i>International Journal of Antimicrobial Agents</i> , 2010, 36, 332-339.	1.1	305
39	Antibiotic resistance—What's dosing got to do with it?. <i>Critical Care Medicine</i> , 2008, 36, 2433-2440.	0.4	299
40	The Epidemiological Profile of Infections with Multidrug-Resistant <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter</i> Species. <i>Clinical Infectious Diseases</i> , 2006, 43, S43-S48.	2.9	292
41	The emerging threat of multidrug-resistant Gram-negative bacteria in urology. <i>Nature Reviews Urology</i> , 2015, 12, 570-584.	1.9	283
42	Community-Associated Extended-Spectrum $\beta$ -Lactamase—Producing <i>Escherichia coli</i> Infection in the United States. <i>Clinical Infectious Diseases</i> , 2013, 56, 641-648.	2.9	276
43	Therapeutic drug monitoring of antimicrobials. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 27-36.	1.1	263
44	Opportunistic Infections in 547 Organ Transplant Recipients Receiving Alemtuzumab, a Humanized Monoclonal CD-52 Antibody. <i>Clinical Infectious Diseases</i> , 2007, 44, 204-212.	2.9	250
45	Tigecycline Efflux as a Mechanism for Nonsusceptibility in <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2065-2069.	1.4	244
46	Trends in Risk Profiles for and Mortality Associated with Invasive Aspergillosis among Liver Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2003, 36, 46-52.	2.9	228
47	Control of an Outbreak of Infection with the Hypervirulent <i>Clostridium difficile</i> BI Strain in a University Hospital Using a Comprehensive "Bundle" Approach. <i>Clinical Infectious Diseases</i> , 2007, 45, 1266-1273.	2.9	224
48	Can Ceftazidime-Avibactam and Aztreonam Overcome $\beta$ -Lactam Resistance Conferred by Metallo- $\beta$ -Lactamases in Enterobacteriaceae?. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	217
49	<i>Acinetobacter baumannii</i> bloodstream infection while receiving tigecycline: a cautionary report. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 59, 128-131.	1.3	216
50	Insights into a Multidrug Resistant <i>Escherichia coli</i> Pathogen of the Globally Disseminated ST131 Lineage: Genome Analysis and Virulence Mechanisms. <i>PLoS ONE</i> , 2011, 6, e26578.	1.1	209
51	Do Human Extraintestinal <i>Escherichia coli</i> Infections Resistant to Expanded-Spectrum Cephalosporins Originate From Food-Producing Animals? A Systematic Review. <i>Clinical Infectious Diseases</i> , 2015, 60, 439-452.	2.9	209
52	New Treatment Options against Carbapenem-Resistant <i>Acinetobacter baumannii</i> Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	208
53	A Multicenter Randomized Trial of Continuous versus Intermittent $\beta$ -Lactam Infusion in Severe Sepsis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 1298-1305.	2.5	206
54	Characterization of blaKPC-containing <i>Klebsiella pneumoniae</i> isolates detected in different institutions in the Eastern USA. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 427-437.	1.3	194

#	ARTICLE	IF	CITATIONS
55	Emergence of High Levels of Extended-Spectrum-β <sup>2</sup> -Lactamase-Producing Gram-Negative Bacilli in the Asia-Pacific Region: Data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Program, 2007. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3280-3284.	1.4	188
56	Antibiotics in the clinical pipeline in October 2019. <i>Journal of Antibiotics</i> , 2020, 73, 329-364.	1.0	188
57	Management of meningitis due to antibiotic-resistant <i>Acinetobacter</i> species. <i>Lancet Infectious Diseases</i> , The, 2009, 9, 245-255.	4.6	185
58	<i>Clostridium difficile</i> PCR ribotype 027: assessing the risks of further worldwide spread. <i>Lancet Infectious Diseases</i> , The, 2010, 10, 395-404.	4.6	178
59	Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 731-741.	4.6	174
60	Carbapenemase-Producing Enterobacteriaceae. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015, 36, 074-084.	0.8	173
61	Dosing guidance for intravenous colistin in critically-ill patients. <i>Clinical Infectious Diseases</i> , 2017, 64, ciw839.	2.9	171
62	Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β <sup>2</sup> -Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 527.	3.8	169
63	Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study <sup>1</sup> . <i>Transplantation</i> , 2003, 75, 2023-2029.	0.5	168
64	The Success of <i>Acinetobacter</i> Species; Genetic, Metabolic and Virulence Attributes. <i>PLoS ONE</i> , 2012, 7, e46984.	1.1	165
65	β <sup>2</sup> -lactam and β <sup>2</sup> -lactamase inhibitor combinations in the treatment of extended-spectrum β <sup>2</sup> -lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 475-485.	4.6	163
66	<i>Aspergillus</i> Galactomannan Antigen in the Bronchoalveolar Lavage Fluid for the Diagnosis of Invasive Aspergillosis in Lung Transplant Recipients. <i>Transplantation</i> , 2007, 83, 1330-1336.	0.5	161
67	INVASIVE ASPERGILLOSIS IN LIVER TRANSPLANT RECIPIENTS IN THE 1990s. <i>Transplantation</i> , 1997, 64, 716-720.	0.5	160
68	Multiresistant Gram-negative infections: a global perspective. <i>Current Opinion in Infectious Diseases</i> , 2010, 23, 546-553.	1.3	159
69	Asymptomatic <i>Clostridium difficile</i> colonization: epidemiology and clinical implications. <i>BMC Infectious Diseases</i> , 2015, 15, 516.	1.3	159
70	Th17 Cells Mediate Clade-Specific, Serotype-Independent Mucosal Immunity. <i>Immunity</i> , 2011, 35, 997-1009.	6.6	158
71	In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 965-973.	1.3	155
72	In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring) Tj ETQq0 0 0 rBT /Overlook 10 Tf		

#	ARTICLE	IF	CITATIONS
73	β <sup>2</sup> -Lactamase Production in Key Gram-Negative Pathogen Isolates from the Arabian Peninsula. <i>Clinical Microbiology Reviews</i> , 2013, 26, 361-380.	5.7	155
74	Systematic Review and Meta-Analysis of the Significance of Heterogeneous Vancomycin-Intermediate <i>Staphylococcus aureus</i> Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 405-410.	1.4	152
75	Colistin resistance: a major breach in our last line of defence. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 132-133.	4.6	152
76	Country-to-Country Transfer of Patients and the Risk of Multi-Resistant Bacterial Infection. <i>Clinical Infectious Diseases</i> , 2011, 53, 49-56.	2.9	150
77	ENCEPHALITIS CAUSED BY HUMAN HERPESVIRUS-6 IN TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 2000, 69, 2474-2479.	0.5	149
78	Genetic Basis of Multidrug Resistance in <i>Acinetobacter baumannii</i> Clinical Isolates at a Tertiary Medical Center in Pennsylvania. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3837-3843.	1.4	145
79	Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?. <i>Clinical Infectious Diseases</i> , 2016, 62, 552-558.	2.9	145
80	Toward Improved Surveillance: The Impact of Ventilator-Associated Complications on Length of Stay and Antibiotic Use in Patients in Intensive Care Units. <i>Clinical Infectious Diseases</i> , 2013, 56, 471-477.	2.9	141
81	Molecular Characterization of Carbapenemase-Producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> in the Countries of the Gulf Cooperation Council: Dominance of OXA-48 and NDM Producers. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3085-3090.	1.4	140
82	A Multinational, Preregistered Cohort Study of β <sup>2</sup> -Lactam/β <sup>2</sup> -Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β <sup>2</sup> -Lactamase-Producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4159-4169.	1.4	137
83	Clinical outcomes of intravenous immune globulin in severe clostridium difficile-associated diarrhea. <i>American Journal of Infection Control</i> , 2007, 35, 131-137.	1.1	134
84	Infectious Complications Following Transrectal Ultrasound-Guided Prostate Biopsy: New Challenges in the Era of Multidrug-Resistant <i>Escherichia coli</i> . <i>Clinical Infectious Diseases</i> , 2013, 57, 267-274.	2.9	127
85	Strategies for Reduction in Duration of Antibiotic Use in Hospitalized Patients. <i>Clinical Infectious Diseases</i> , 2011, 52, 1232-1240.	2.9	125
86	Comorbidities, Exposure to Medications, and the Risk of Community-Acquired <i>Clostridium difficile</i> Infection: A Systematic Review and Meta-analysis. <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 132-141.	1.0	123
87	Clinical outcomes and bacterial characteristics of carbapenem-resistant <i>Klebsiella pneumoniae</i> complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 401-412.	4.6	122
88	Simple Disk-Based Method for Detection of <i>Klebsiella pneumoniae</i> Carbapenemase-Type β <sup>2</sup> -Lactamase by Use of a Boronic Acid Compound. <i>Journal of Clinical Microbiology</i> , 2008, 46, 4083-4086.	1.8	120
89	A Step Closer to Extreme Drug Resistance (XDR) in Gram-Negative Bacilli. <i>Clinical Infectious Diseases</i> , 2007, 45, 1179-1181.	2.9	119
90	Molecular Epidemiology of CTX-M-Producing <i>Escherichia coli</i> Isolates at a Tertiary Medical Center in Western Pennsylvania. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 4733-4739.	1.4	116

#	ARTICLE	IF	CITATIONS
91	Stepwise evolution of pandrug-resistance in <i>Klebsiella pneumoniae</i> . <i>Scientific Reports</i> , 2015, 5, 15082.	1.6	115
92	Carbapenem Resistance in <i>Klebsiella pneumoniae</i> Due to the New Delhi Metallo- $\beta$ -lactamase. <i>Clinical Infectious Diseases</i> , 2011, 52, 481-484.	2.9	114
93	Failure of Current Cefepime Breakpoints To Predict Clinical Outcomes of Bacteremia Caused by Gram-Negative Organisms. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 4390-4395.	1.4	113
94	Health care-associated pneumonia: identification and initial management in the ED. <i>American Journal of Emergency Medicine</i> , 2008, 26, 1-11.	0.7	112
95	Health Care-associated Pneumonia (HCAP): A Critical Appraisal to Improve Identification, Management, and Outcomes Proceedings of the HCAP Summit. <i>Clinical Infectious Diseases</i> , 2008, 46, S296-S334.	2.9	111
96	Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?. <i>Critical Care</i> , 2015, 19, 28.	2.5	111
97	Protein-inspired antibiotics active against vancomycin- and daptomycin-resistant bacteria. <i>Nature Communications</i> , 2018, 9, 22.	5.8	111
98	Clinically Relevant Plasma Concentrations of Colistin in Combination with Imipenem Enhance Pharmacodynamic Activity against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> at Multiple Inocula. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5134-5142.	1.4	109
99	<i>Escherichia coli</i> Bloodstream Infection After Transrectal Ultrasound-Guided Prostate Biopsy: Implications of Fluoroquinolone-Resistant Sequence Type 131 as a Major Causative Pathogen. <i>Clinical Infectious Diseases</i> , 2012, 54, 1406-1412.	2.9	109
100	Health Risks of Flood Disasters. <i>Clinical Infectious Diseases</i> , 2018, 67, 1450-1454.	2.9	108
101	Infections with Nontyphoidal <i>Salmonella</i> Species Producing TEM-63 or a Novel TEM Enzyme, TEM-131, in South Africa. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 4263-4270.	1.4	107
102	Synergistic Killing of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> at Multiple Inocula by Colistin Combined with Doripenem in an In Vitro Pharmacokinetic/Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5685-5695.	1.4	107
103	PREEMPTIVE PROPHYLAXIS WITH A LIPID PREPARATION OF AMPHOTERICIN B FOR INVASIVE FUNGAL INFECTIONS IN LIVER TRANSPLANT RECIPIENTS REQUIRING RENAL REPLACEMENT THERAPY <sup>1</sup> . <i>Transplantation</i> , 2001, 71, 910-913.	0.5	106
104	Prevalence of multidrug-resistant organisms and risk factors for carriage in long-term care facilities: a nested case-control study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1972-1980.	1.3	106
105	Identification of IncA/C Plasmid Replication and Maintenance Genes and Development of a Plasmid Multilocus Sequence Typing Scheme. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	106
106	Interactions Between Tacrolimus and Antimicrobial Agents. <i>Clinical Infectious Diseases</i> , 1997, 25, 1430-1440.	2.9	104
107	Risk factors for toxicity in elderly patients given aminoglycosides once daily. <i>Journal of General Internal Medicine</i> , 1998, 13, 735-739.	1.3	104
108	Empirical Antibiotic Choice for the Seriously Ill Patient: Are Minimization of Selection of Resistant Organisms and Maximization of Individual Outcome Mutually Exclusive?. <i>Clinical Infectious Diseases</i> , 2003, 36, 1006-1012.	2.9	104



#	ARTICLE	IF	CITATIONS
109	Infective Endocarditis in Solid Organ Transplant Recipients. <i>Clinical Infectious Diseases</i> , 1998, 26, 689-694.	2.9	103
110	Measurement of Adherence to Antiretroviral Medications. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 31, S103-S106.	0.9	103
111	Molecular Epidemiology of Carbapenem-Resistant <i>Acinetobacter baumannii</i> Isolates in the Gulf Cooperation Council States: Dominance of OXA-23-Type Producers. <i>Journal of Clinical Microbiology</i> , 2015, 53, 896-903.	1.8	103
112	Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> : a pooled analysis of Phase 3 clinical trials. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 268-272.	1.3	103
113	Parenteral and Inhaled Colistin for Treatment of Ventilator-Associated Pneumonia. <i>Clinical Infectious Diseases</i> , 2006, 43, S89-S94.	2.9	102
114	Successful Outcome of Human Metapneumovirus (hMPV) Pneumonia in a Lung Transplant Recipient Treated With Intravenous Ribavirin. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, 862-864.	0.3	102
115	Extensively Drug-Resistant <i>Acinetobacter baumannii</i> . <i>Emerging Infectious Diseases</i> , 2009, 15, 980-982.	2.0	101
116	Coproduction of Novel 16S rRNA Methylase RmtD and Metallo- $\beta$ -Lactamase SPM-1 in a Panresistant <i>Pseudomonas aeruginosa</i> Isolate from Brazil. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 852-856.	1.4	99
117	CENTRAL NERVOUS SYSTEM LESIONS IN LIVER TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 1998, 66, 1596-1604.	0.5	98
118	Uropathogenic <i>Escherichia coli</i> Mediated Urinary Tract Infection. <i>Current Drug Targets</i> , 2012, 13, 1386-1399.	1.0	97
119	Clinical Population Pharmacokinetics and Toxicodynamics of Linezolid. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2334-2343.	1.4	96
120	Integron-mediated Multidrug Resistance in a Global Collection of Nontyphoidal <i>Salmonella enterica</i> Isolates. <i>Emerging Infectious Diseases</i> , 2009, 15, 388-396.	2.0	94
121	Interspecies Spread of <i>Klebsiella pneumoniae</i> Carbapenemase Gene in a Single Patient. <i>Clinical Infectious Diseases</i> , 2009, 49, 1736-1738.	2.9	94
122	Baseline prevalence of antimicrobial resistance and subsequent infection following prostate biopsy using empirical or altered prophylaxis: A bias-adjusted meta-analysis. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 301-309.	1.1	93
123	Redefining extended-spectrum $\beta$ -lactamases: balancing science and clinical need. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 63, 1-4.	1.3	92
124	CYTOMEGALOVIRUS ANTIGENEMIA DIRECTED PRE-EMPTIVE PROPHYLAXIS WITH ORAL VERSUS I.V. GANCICLOVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN LIVER TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 2000, 70, 717-722.	0.5	89
125	Presence of Plasmid-Mediated Quinolone Resistance in <i>Klebsiella pneumoniae</i> Isolates Possessing <i>bla</i> KPC in the United States. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2680-2682.	1.4	89
126	Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). <i>International Journal of Antimicrobial Agents</i> , 2010, 36, 408-414.	1.1	89



#	ARTICLE	IF	CITATIONS
127	Identification and molecular characterisation of New Delhi metallo-β-lactamase-1 (NDM-1)- and NDM-6-producing Enterobacteriaceae from New Zealand hospitals. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 529-533.	1.1	89
128	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1362-1371.	1.4	89
129	Infections in Hematopoietic Cell Transplant Recipients: Results From the Organ Transplant Infection Project, a Multicenter, Prospective, Cohort Study. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx050.	0.4	89
130	<i>Scedosporium prolificans</i> brain abscess in a patient with chronic granulomatous disease: Successful combination therapy with voriconazole and terbinafine. <i>Scandinavian Journal of Infectious Diseases</i> , 2007, 39, 87-90.	1.5	88
131	Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria. <i>Journal of Infection</i> , 2011, 62, 280-291.	1.7	88
132	An environmental cleaning bundle and health-care-associated infections in hospitals (REACH): a multicentre, randomised trial. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 410-418.	4.6	86
133	Epidemiological Profile of Linezolid-Resistant Coagulase-Negative Staphylococci. <i>Clinical Infectious Diseases</i> , 2006, 43, 165-171.	2.9	85
134	The Combination of Colistin and Doripenem Is Synergistic against <i>Klebsiella pneumoniae</i> at Multiple Inocula and Suppresses Colistin Resistance in an <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5103-5112.	1.4	85
135	Doripenem. <i>Clinical Infectious Diseases</i> , 2009, 49, 291-298.	2.9	84
136	Vancomycin Heteroresistance Is Associated with Reduced Mortality in ST239 Methicillin-Resistant <i>Staphylococcus aureus</i> Blood Stream Infections. <i>PLoS ONE</i> , 2011, 6, e21217.	1.1	84
137	What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 455-457.	1.1	84
138	Outer Membrane Protein Changes and Efflux Pump Expression Together May Confer Resistance to Ertapenem in <i>Enterobacter cloacae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 2833-2835.	1.4	83
139	<i>Achromobacter</i> Infections and Treatment Options. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	82
140	Multidrug-Resistant Bacteria in the Community. <i>Infectious Disease Clinics of North America</i> , 2020, 34, 709-722.	1.9	81
141	Identification of Novel Vaccine Candidates against Multidrug-Resistant <i>Acinetobacter baumannii</i> . <i>PLoS ONE</i> , 2013, 8, e77631.	1.1	80
142	Association between augmented renal clearance and clinical outcomes in patients receiving β-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 624-630.	1.1	80
143	Dominance of IMP-4-Producing <i>Enterobacter cloacae</i> among Carbapenemase-Producing Enterobacteriaceae in Australia. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4059-4066.	1.4	78
144	Molecular Epidemiology of Multidrug-Resistant <i>Acinetobacter baumannii</i> in a Single Institution over a 10-Year Period. <i>Journal of Clinical Microbiology</i> , 2010, 48, 4051-4056.	1.8	76

#	ARTICLE	IF	CITATIONS
145	The spread and acquisition of NDM-1: a multifactorial problem. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 91-115.	2.0	76
146	Impact of Antibiotic Resistance in Gram-Negative Bacilli on Empirical and Definitive Antibiotic Therapy. <i>Clinical Infectious Diseases</i> , 2008, 47, S14-S20.	2.9	74
147	Diagnosis of Human Metapneumovirus Infection in Immunosuppressed Lung Transplant Recipients and Children Evaluated for Pertussis. <i>Journal of Clinical Microbiology</i> , 2007, 45, 548-552.	1.8	73
148	Synergistic killing of NDM-producing MDR <i>Klebsiella pneumoniae</i> by two "old" antibiotics polymyxin B and chloramphenicol. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2589-2597.	1.3	73
149	Detection of plasmid-mediated class C $\beta$ -lactamases. <i>International Journal of Infectious Diseases</i> , 2007, 11, 191-197.	1.5	71
150	Treatment Options for New Delhi Metallo-Beta-Lactamase-Harboring Enterobacteriaceae. <i>Microbial Drug Resistance</i> , 2013, 19, 100-103.	0.9	71
151	High prevalence of CTX-M-15-producing <i>Klebsiella pneumoniae</i> among inpatients and outpatients with urinary tract infection in Southern India. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 1393-1394.	1.3	68
152	Performance of Various Testing Methodologies for Detection of Heteroresistant Vancomycin-Intermediate <i>Staphylococcus aureus</i> in Bloodstream Isolates. <i>Journal of Clinical Microbiology</i> , 2011, 49, 1489-1494.	1.8	68
153	Molecular Analysis of the <i>Acinetobacter baumannii</i> Biofilm-Associated Protein. <i>Applied and Environmental Microbiology</i> , 2013, 79, 6535-6543.	1.4	68
154	The increased risks of death and extra lengths of hospital and ICU stay from hospital-acquired bloodstream infections: a case-control study. <i>BMJ Open</i> , 2013, 3, e003587.	0.8	68
155	Risk factors and outcome of extended-spectrum $\beta$ -lactamase-producing <i>Enterobacter cloacae</i> bloodstream infections. <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 26-32.	1.1	66
156	A Change in the Epidemiology of Infections Due to Extended-Spectrum $\beta$ -Lactamase-Producing Organisms. <i>Clinical Infectious Diseases</i> , 2006, 42, 935-937.	2.9	65
157	Pharmacokinetic evaluation of piperacillin-tazobactam. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 1017-1031.	1.5	65
158	Failure to detect chlamydia pneumoniae in atherosclerotic plaques of Australian patients. <i>Pathology</i> , 1998, 30, 169-172.	0.3	64
159	Intrapulmonary Penetration of Voriconazole in Patients Receiving an Oral Prophylactic Regimen. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1878-1880.	1.4	64
160	Identification of 16S rRNA Methylase-Producing <i>Acinetobacter baumannii</i> Clinical Strains in North America. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 4209-4210.	1.4	64
161	Genomic Characteristics of NDM-Producing Enterobacteriaceae Isolates in Australia and Their NDM Genetic Contexts. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 136-141.	1.4	64
162	Editorial Commentary: Looking for Risk Factors for the Acquisition of Antibiotic Resistance: A 21st-Century Approach. <i>Clinical Infectious Diseases</i> , 2002, 34, 1564-1567.	2.9	62

#	ARTICLE	IF	CITATIONS
163	Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by <i>Enterobacter</i> , <i>Citrobacter</i> or <i>Serratia</i> species: a systematic review with meta-analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 296-306.	1.3	62
164	CAMERA2 – combination antibiotic therapy for methicillin-resistant <i>Staphylococcus aureus</i> infection: study protocol for a randomised controlled trial. <i>Trials</i> , 2016, 17, 170.	0.7	61
165	Spread of MCR-3 Colistin Resistance in China: An Epidemiological, Genomic and Mechanistic Study. <i>EBioMedicine</i> , 2018, 34, 139-157.	2.7	61
166	Clarithromycin Versus Azithromycin in the Treatment of Mediterranean Spotted Fever in Children: A Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2002, 34, 154-158.	2.9	60
167	Lack of efficacy of mupirocin in the prevention of infections with <i>staphylococcus aureus</i> in liver transplant recipients and candidates <sup>1</sup> . <i>Transplantation</i> , 2003, 75, 194-198.	0.5	60
168	Consistent Global Approach on Reporting of Colistin Doses to Promote Safe and Effective Use. <i>Clinical Infectious Diseases</i> , 2014, 58, 139-141.	2.9	60
169	Pharmacokinetic/Toxicodynamic Analysis of Colistin-Associated Acute Kidney Injury in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	60
170	Multiclonal Outbreak of <i>Klebsiella pneumoniae</i> Producing Extended-Spectrum $\beta$ -Lactamase CTX-M-2 and Novel Variant CTX-M-59 in a Neonatal Intensive Care Unit in Brazil. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1790-1793.	1.4	59
171	INFECTIOUS COMPLICATIONS OCCURRING IN LIVER TRANSPLANT RECIPIENTS RECEIVING MYCOPHENOLATE MOFETIL. <i>Transplantation</i> , 1998, 66, 593-598.	0.5	58
172	Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible <i>Escherichia coli</i> and <i>Klebsiella</i> spp (the MERINO trial): study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 24.	0.7	57
173	Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use: systematic review and meta-analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 72, dkw459.	1.3	57
174	SHV-Type Extended-Spectrum Beta-Lactamase Production Is Associated with Reduced Cefepime Susceptibility in <i>Enterobacter cloacae</i> . <i>Journal of Clinical Microbiology</i> , 2005, 43, 5058-5064.	1.8	56
175	OqxAB, a Quinolone and Olaquinox Efflux Pump, Is Widely Distributed among Multidrug-Resistant <i>Klebsiella pneumoniae</i> Isolates of Human Origin. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4602-4603.	1.4	56
176	Whole genome analysis of cephalosporin-resistant <i>Escherichia coli</i> from bloodstream infections in Australia, New Zealand and Singapore: high prevalence of CMY-2 producers and ST131 carrying blaCTX-M-15 and blaCTX-M-27. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 634-642.	1.3	56
177	Clinical experience with recently approved antibiotics. <i>Current Opinion in Pharmacology</i> , 2006, 6, 486-490.	1.7	55
178	Genotypic and phenotypic identification of <i>Aeromonas</i> species and CphA-mediated carbapenem resistance in Queensland, Australia. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 85, 98-101.	0.8	55
179	COVID-19 – Lessons Learned and Questions Remaining. <i>Clinical Infectious Diseases</i> , 2021, 72, 2225-2240.	2.9	54
180	Characteristics of bloodstream infections in burn patients: An 11-year retrospective study. <i>Burns</i> , 2012, 38, 685-690.	1.1	53

#	ARTICLE	IF	CITATIONS
181	Ampicillin/sulbactam: Its potential use in treating infections in critically ill patients. <i>International Journal of Antimicrobial Agents</i> , 2013, 42, 384-389.	1.1	53
182	Challenges for Standardization of <i>Clostridium difficile</i> Typing Methods. <i>Journal of Clinical Microbiology</i> , 2013, 51, 2810-2814.	1.8	53
183	Long-term morbidity and mortality following bloodstream infection: A systematic literature review. <i>Journal of Infection</i> , 2018, 77, 1-8.	1.7	53
184	Methicillin-resistant <i>Staphylococcus aureus</i> vancomycin susceptibility testing: methodology correlations, temporal trends and clonal patterns. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2284-2287.	1.3	52
185	Upper Versus Lower Gastrointestinal Delivery for Transplantation of Fecal Microbiota in Recurrent or Refractory <i>Clostridium difficile</i> Infection. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 145-150.	1.1	52
186	Pulmonary Nodules in Liver Transplant Recipients. <i>Medicine (United States)</i> , 1998, 77, 50-58.	0.4	51
187	Quality of life in long-term survivors after liver transplantation: impact of recurrent viral hepatitis C virus hepatitis 1. <i>Clinical Transplantation</i> , 2000, 14, 48-54.	0.8	51
188	Determination of Risk Factors Associated With Isolation of Linezolid-Resistant Strains of Vancomycin-Resistant <i>Enterococcus</i> . <i>Infection Control and Hospital Epidemiology</i> , 2007, 28, 1382-1388.	1.0	51
189	Cost-Effectiveness of a Central Venous Catheter Care Bundle. <i>PLoS ONE</i> , 2010, 5, e12815.	1.1	50
190	Comparable outcomes for $\beta$ -lactam/ $\beta$ -lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant <i>Escherichia coli</i> or <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Resistance and Infection Control</i> , 2015, 4, 14.	1.5	50
191	Draft Genome Sequence of NDM-5-Producing <i>Escherichia coli</i> Sequence Type 648 and Genetic Context of bla NDM-5 in Australia. <i>Genome Announcements</i> , 2015, 3, .	0.8	50
192	Multihospital Occurrence of Pan-Resistant <i>Klebsiella pneumoniae</i> Sequence Type 147 with an IS <i>Ecp1</i> -Directed <i>bla</i> <sub>OXA-181</sub> Insertion in the <i>mgrB</i> Gene in the United Arab Emirates. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	50
193	Antimicrobial treatment challenges in the era of carbapenem resistance. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 94, 413-425.	0.8	50
194	Culture-independent detection systems for bloodstream infection. <i>Clinical Microbiology and Infection</i> , 2022, 28, 195-201.	2.8	50
195	Relationship of cytomegalovirus load assessed by real-time PCR to pp65 antigenemia in organ transplant recipients. <i>Journal of Clinical Virology</i> , 2008, 42, 335-342.	1.6	49
196	In Vitro Susceptibilities of Aerobic and Facultatively Anaerobic Gram-Negative Bacilli Isolated from Patients with Intra-Abdominal Infections Worldwide: 2005 Results from Study for Monitoring Antimicrobial Resistance Trends (SMART). <i>Surgical Infections</i> , 2009, 10, 99-104.	0.7	49
197	Prevalence and molecular characterization of Enterobacteriaceae producing NDM-1 carbapenemase at a military hospital in Pakistan and evaluation of two chromogenic media. <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 75, 187-191.	0.8	49
198	Characterization of an IncN2-type blaNDM-1-carrying plasmid in <i>Escherichia coli</i> ST131 and <i>Klebsiella pneumoniae</i> ST11 and ST15 isolates in Thailand. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3161-3163.	1.3	49

#	ARTICLE	IF	CITATIONS
199	Surveillance for antimicrobial resistance in Australian isolates of <i>Clostridium difficile</i> , 2013–14. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2992-2999.	1.3	49
200	Mechanisms Involved in Acquisition of <i>bla</i> <sub>NDM</sub> Genes by IncA/C <sub>2</sub> and IncFII <sub>Y</sub> Plasmids. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4082-4088.	1.4	49
201	Hospital-wide Eradication of a Nosocomial <i>Legionella pneumophila</i> Serogroup 1 Outbreak. <i>Clinical Infectious Diseases</i> , 2016, 62, 273-279.	2.9	49
202	Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing <i>Escherichia coli</i> and ESBL-Producing <i>Klebsiella pneumoniae</i> . <i>Infection Control and Hospital Epidemiology</i> , 2018, 39, 660-667.	1.0	49
203	High Prevalence of Metallo- $\beta$ -Lactamase and 16S rRNA Methylase Coproduction among Imipenem-Resistant <i>Pseudomonas aeruginosa</i> Isolates in Brazil. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3388-3390.	1.4	48
204	Molecular Epidemiology and Mechanisms of Carbapenem Resistance of <i>Acinetobacter</i> spp. in Asia and Oceania. <i>Microbial Drug Resistance</i> , 2015, 21, 424-434.	0.9	48
205	Discovery of <i>mcr-1</i> -Mediated Colistin Resistance in a Highly Virulent <i>Escherichia coli</i> Lineage. <i>MSphere</i> , 2018, 3, .	1.3	48
206	Effect of Parenteral Antibiotic Administration on Establishment of Intestinal Colonization in Mice by <i>Klebsiella pneumoniae</i> Strains Producing Extended-Spectrum $\beta$ -Lactamases. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 3610-3612.	1.4	47
207	Effect of the Increasing Use of Piperacillin/Tazobactam on the Incidence of Vancomycin-Resistant Enterococci in Four Academic Medical Centers. <i>Infection Control and Hospital Epidemiology</i> , 2004, 25, 380-383.	1.0	47
208	Genetic Contexts of <i>bla</i> <sub>NDM-1</sub> in Patients Carrying Multiple NDM-Producing Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7405-7410.	1.4	47
209	Extended-spectrum beta-lactamases: the European experience. <i>Current Opinion in Infectious Diseases</i> , 2001, 14, 697-701.	1.3	46
210	Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum- $\beta$ -lactamase-producing Enterobacteriaceae. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw513.	1.3	46
211	Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. <i>BMC Infectious Diseases</i> , 2021, 21, 1170.	1.3	46
212	Characterization of a Naturally Occurring Class D $\beta$ -Lactamase from <i>Achromobacter xylosoxidans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1952-1956.	1.4	45
213	Clinical Features and Molecular Epidemiology of CMY $\beta$ -type $\beta$ -Lactamase-Producing <i>Escherichia coli</i> . <i>Clinical Infectious Diseases</i> , 2009, 48, 739-744.	2.9	45
214	Control of an Outbreak of Carbapenem-Resistant <i>Acinetobacter baumannii</i> in Australia after Introduction of Environmental Cleaning with a Commercial Oxidizing Disinfectant. <i>Infection Control and Hospital Epidemiology</i> , 2010, 31, 418-420.	1.0	44
215	Characterisation of clinical and food animal <i>Escherichia coli</i> isolates producing CTX-M-15 extended-spectrum $\beta$ -lactamase belonging to ST410 phylogroup A. <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 365-367.	1.1	44
216	Identification of carbapenem-resistant <i>Pseudomonas aeruginosa</i> in selected hospitals of the Gulf Cooperation Council States: dominance of high-risk clones in the region. <i>Journal of Medical Microbiology</i> , 2018, 67, 846-853.	0.7	44

#	ARTICLE	IF	CITATIONS
217	Intrapulmonary Disposition of Amphotericin B After Aerosolized Delivery of Amphotericin B Lipid Complex (Abelcet; ABLC) in Lung Transplant Recipients. <i>Transplantation</i> , 2010, 90, 1215-1219.	0.5	43
218	Enhancing Resistance to Cephalosporins in Class C $\beta$ -Lactamases: Impact of Gly214Glu in CMY-2. <i>Biochemistry</i> , 2010, 49, 1014-1023.	1.2	43
219	Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients. <i>BMC Anesthesiology</i> , 2011, 11, 3.	0.7	43
220	Enhancement of antibiotic-activity through complexation with metal ions - Combined ITC, NMR, enzymatic and biological studies. <i>Journal of Inorganic Biochemistry</i> , 2017, 167, 134-141.	1.5	43
221	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum $\beta$ -Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort. <i>Clinical Infectious Diseases</i> , 2017, 65, 1615-1623.	2.9	43
222	Activity of Temocillin against KPC-Producing <i>Klebsiella pneumoniae</i> and <i>Escherichia coli</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2700-2701.	1.4	41
223	<i>Escherichia coli</i> ST131 producing CTX-M-15 in Australia. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1301-1303.	1.3	41
224	Effectiveness of H1N1/09 monovalent and trivalent influenza vaccines against hospitalization with laboratory-confirmed H1N1/09 influenza in Australia: A test-negative case control study. <i>Vaccine</i> , 2011, 29, 7320-7325.	1.7	41
225	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1672-1680.	1.3	41
226	Modifications in the pmrB gene are the primary mechanism for the development of chromosomally encoded resistance to polymyxins in uropathogenic <i>Escherichia coli</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2729-2736.	1.3	41
227	Community-acquired Extended-Spectrum $\beta$ -Lactamase Producers, United States. <i>Emerging Infectious Diseases</i> , 2007, 13, 1121-1123.	2.0	40
228	Cost effectiveness of antimicrobial catheters in the intensive care unit: addressing uncertainty in the decision. <i>Critical Care</i> , 2009, 13, R35.	2.5	40
229	Expansive spread of IncI1 plasmids carrying blaCMY-2 amongst <i>Escherichia coli</i> . <i>International Journal of Antimicrobial Agents</i> , 2014, 44, 203-208.	1.1	40
230	Bloodstream infections in organ transplant recipients receiving alemtuzumab: No evidence of occurrence of organisms typically associated with profound T cell depletion. <i>Journal of Infection</i> , 2006, 53, 241-247.	1.7	39
231	First Case of Bloodstream Infection Caused by <i>Rhodococcus erythropolis</i> . <i>Journal of Clinical Microbiology</i> , 2009, 47, 2667-2669.	1.8	39
232	<i>Pseudomonas aeruginosa</i> infections in the Intensive Care Unit: can the adequacy of empirical $\beta$ -lactam antibiotic therapy be improved?. <i>International Journal of Antimicrobial Agents</i> , 2007, 30, 458-462.	1.1	38
233	Post-transplant Colonization With Non-Aspergillus Molds and Risk of Development of Invasive Fungal Disease in Lung Transplant Recipients. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 850-855.	0.3	38
234	Antimicrobial chemotherapy and lung microdialysis: a review. <i>International Journal of Antimicrobial Agents</i> , 2010, 36, 491-500.	1.1	38



#	ARTICLE	IF	CITATIONS
235	Clinical Characteristics of Bloodstream Infections Due to Ampicillin-Sulbactam-Resistant, Non-Extended-Spectrum- $\beta$ -Lactamase-Producing <i>Escherichia coli</i> and the Role of TEM-1 Hyperproduction. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 495-501.	1.4	38
236	Molecular Epidemiology of NDM-1-Producing Enterobacteriaceae and <i>Acinetobacter baumannii</i> Isolates from Pakistan. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5589-5593.	1.4	38
237	Mechanisms of hypervirulent <i>Clostridium difficile</i> ribotype O27 displacement of endemic strains: an epidemiological model. <i>Scientific Reports</i> , 2015, 5, 12666.	1.6	38
238	Effect of different renal function on antibacterial effects of piperacillin against <i>Pseudomonas aeruginosa</i> evaluated via the hollow-fibre infection model and mechanism-based modelling. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2509-2520.	1.3	38
239	Fracture-related infection: current methods for prevention and treatment. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 307-321.	2.0	38
240	Dyslipidaemia in HIV-infected patients: association with adherence to potent antiretroviral therapy. <i>International Journal of STD and AIDS</i> , 2001, 12, 463-468.	0.5	37
241	<i>Clostridium difficile</i> Infection Seasonality: Patterns across Hemispheres and Continents – A Systematic Review. <i>PLoS ONE</i> , 2015, 10, e0120730.	1.1	37
242	Genomic Investigation Reveals Contaminated Detergent as the Source of an Extended-Spectrum- $\beta$ -Lactamase-Producing <i>Klebsiella michiganensis</i> Outbreak in a Neonatal Unit. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	37
243	Encephalopathy associated with human herpesvirus 6 in a liver transplant recipient. <i>Liver Transplantation</i> , 1999, 5, 454-455.	1.9	36
244	Optimizing Therapy for Infections Caused by Enterobacteriaceae Producing Extended-Spectrum $\beta$ -Lactamases. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2007, 28, 646-655.	0.8	36
245	<i>Clostridium difficile</i> exposure as an insidious source of infection in healthcare settings: an epidemiological model. <i>BMC Infectious Diseases</i> , 2013, 13, 376.	1.3	35
246	A New Marker of Sepsis Post Burn Injury?*. <i>Critical Care Medicine</i> , 2014, 42, 2029-2036.	0.4	35
247	Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	34
248	Integrating multiple genomic technologies to investigate an outbreak of carbapenemase-producing <i>Enterobacter hormaechei</i> . <i>Nature Communications</i> , 2020, 11, 466.	5.8	34
249	Zoonotic Disease in Australia Caused by a Novel Member of the Paramyxoviridae. <i>Clinical Infectious Diseases</i> , 1998, 27, 112-118.	2.9	33
250	Returning to the pre-antibiotic era in the critically ill: The XDR problem*. <i>Critical Care Medicine</i> , 2007, 35, 1789-1791.	0.4	33
251	CTX-M-2-Producing <i>Salmonella</i> Typhimurium Isolated from Pediatric Patients and Poultry in Brazil. <i>Microbial Drug Resistance</i> , 2009, 15, 317-321.	0.9	33
252	Community-Onset <i>Escherichia coli</i> Infection Resistant to Expanded-Spectrum Cephalosporins in Low-Prevalence Countries. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2126-2134.	1.4	33



#	ARTICLE	IF	CITATIONS
253	Multidrug-resistant <i>Escherichia coli</i> in Asia: epidemiology and management. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 575-591.	2.0	33
254	Transmission of <i>mcr-1</i> -Producing Multidrug-resistant Enterobacteriaceae in Public Transportation in Guangzhou, China. <i>Clinical Infectious Diseases</i> , 2018, 67, S217-S224.	2.9	33
255	Risk factors for mortality among patients with <i>Pseudomonas aeruginosa</i> bacteraemia: a retrospective multicentre study. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105847.	1.1	33
256	Should third-generation cephalosporins be avoided against AmpC-inducible Enterobacteriaceae?. <i>Clinical Microbiology and Infection</i> , 2004, 10, 84-85.	2.8	32
257	Acquisition of Rectal Colonization by Vancomycin-Resistant <i>Enterococcus</i> among Intensive Care Unit Patients Treated with Piperacillin-Tazobactam versus Those Receiving Cefepime-Containing Antibiotic Regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 465-469.	1.4	32
258	New Gram-positive antibiotics. <i>Current Opinion in Infectious Diseases</i> , 2011, 24, 515-520.	1.3	32
259	INTRAOPERATIVE HYPOTHERMIA IS AN INDEPENDENT RISK FACTOR FOR EARLY CYTOMEGALOVIRUS INFECTION IN LIVER TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 1999, 67, 1151-1155.	0.5	32
260	The Potential Role of Social Media Platforms in Community Awareness of Antibiotic Use in the Gulf Cooperation Council States: Luxury or Necessity?. <i>Journal of Medical Internet Research</i> , 2015, 17, e233.	2.1	32
261	Guideline of guidelines: management of recurrent urinary tract infections in women. <i>BJU International</i> , 2022, 130, 11-22.	1.3	32
262	Monitoring the global in vitro activity of ertapenem against <i>Escherichia coli</i> from intra-abdominal infections: SMART 2002-2010. <i>International Journal of Antimicrobial Agents</i> , 2013, 41, 224-228.	1.1	31
263	Copper Ions and Coordination Complexes as Novel Carbapenem Adjuvants. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	31
264	Antimicrobial stewardship activities: a survey of Queensland hospitals. <i>Australian Health Review</i> , 2014, 38, 557.	0.5	30
265	An update on cefepime and its future role in combination with novel $\beta$ -lactamase inhibitors for MDR Enterobacterales and <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 550-560.	1.3	30
266	Interaction of daptomycin with two recombinant thromboplastin reagents leads to falsely prolonged patient prothrombin time/International Normalized Ratio results. <i>Blood Coagulation and Fibrinolysis</i> , 2008, 19, 32-38.	0.5	29
267	Reduced Susceptibility to Cefepime among <i>Escherichia coli</i> Clinical Isolates Producing Novel Variants of CMY-2 $\beta$ -Lactamase. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3159-3161.	1.4	29
268	Changes in knowledge and attitudes of hospital environmental services staff: The Researching Effective Approaches to Cleaning in Hospitals (REACH) study. <i>American Journal of Infection Control</i> , 2018, 46, 980-985.	1.1	29
269	Pulmonary fungal infections. <i>Current Opinion in Pulmonary Medicine</i> , 2005, 11, 242-246.	1.2	28
270	How Soon Is Now? The Urgent Need for Randomized, Controlled Trials Evaluating Treatment of Multidrug-Resistant Bacterial Infection. <i>Clinical Infectious Diseases</i> , 2010, 51, 1245-1247.	2.9	28

#	ARTICLE	IF	CITATIONS
271	Researching effective approaches to cleaning in hospitals: protocol of the REACH study, a multi-site stepped-wedge randomised trial. <i>Implementation Science</i> , 2015, 11, 44.	2.5	28
272	Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1195-1216.	1.6	28
273	Budget impact analysis of routinely using whole-genomic sequencing of six multidrug-resistant bacterial pathogens in Queensland, Australia. <i>BMJ Open</i> , 2021, 11, e041968.	0.8	28
274	Serious infections caused by enteric gram-negative bacilli-Mechanisms of antibiotic resistance and implications for therapy of gram-negative sepsis in the transplanted patient. <i>Seminars in Respiratory Infections</i> , 2002, 17, 260-264.	1.3	28
275	In Vitro Susceptibilities of <i>Escherichia coli</i> Isolated from Patients with Intra-Abdominal Infections Worldwide in 2002-2004: Results from SMART (Study for Monitoring Antimicrobial Resistance) Tj ETQq1 1 0.784314 rgBT2/Overlook	0.7	27
276	Pharmacokinetics of Beta-Lactam Antibiotics in Patients with Intra-Abdominal Disease: A Structured Review. <i>Surgical Infections</i> , 2012, 13, 9-17.	0.7	27
277	Comparative Genomics and Antimicrobial Resistance Profiling of <i>Elizabethkingia</i> Isolates Reveal Nosocomial Transmission and <i>In Vitro</i> Susceptibility to Fluoroquinolones, Tetracyclines, and Trimethoprim-Sulfamethoxazole. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	27
278	All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 707-719.	2.0	27
279	<i>Escherichia coli</i> Isolate Coproducing 16S rRNA Methylase and CTX-M-Type Extended-Spectrum $\beta$ -Lactamase Isolated from an Outpatient in the United States. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1204-1205.	1.4	26
280	Intercontinental transfer of OXA-181-producing <i>Klebsiella pneumoniae</i> into New Zealand. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2888-2890.	1.3	26
281	Community-associated Methicillin-resistant <i>Staphylococcus aureus</i> Causing Orbital Cellulitis in Australian Children. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 1003-1006.	1.1	26
282	Risk factors for relapse or persistence of bacteraemia caused by <i>Enterobacter</i> spp.: a case-control study. <i>Antimicrobial Resistance and Infection Control</i> , 2017, 6, 14.	1.5	26
283	Oral cephalosporin and $\beta$ -lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2384-2393.	1.3	26
284	Meropenem Administered as a Prolonged Infusion to Treat Serious Gram-Negative Central Nervous System Infections. <i>Pharmacotherapy</i> , 2004, 24, 803-807.	1.2	25
285	MicroPIPE: validating an end-to-end workflow for high-quality complete bacterial genome construction. <i>BMC Genomics</i> , 2021, 22, 474.	1.2	25
286	Pharmacokinetics of meropenem and piperacillin in critically ill patients with indwelling surgical drains. <i>International Journal of Antimicrobial Agents</i> , 2013, 42, 90-93.	1.1	24
287	Community-Acquired Pyelonephritis in Pregnancy Caused by KPC-Producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4375-4378.	1.4	24
288	A Case of IMP-4-, OXA-421-, OXA-96-, and CARB-2-Producing <i>Acinetobacter pittii</i> Sequence Type 119 in Australia. <i>Journal of Clinical Microbiology</i> , 2015, 53, 727-730.	1.8	24

#	ARTICLE	IF	CITATIONS
289	Assessing control bundles for <i>Clostridium difficile</i> : a review and mathematical model. <i>Emerging Microbes and Infections</i> , 2014, 3, 1-8.	3.0	23
290	Interspecies Transfer of <i>bla</i> <sub>IMP-4</sub> in a Patient with Prolonged Colonization by IMP-4-Producing Enterobacteriaceae. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3816-3818.	1.8	23
291	Multiplex PCR to detect the genes encoding naturally occurring oxacillinases in <i>Acinetobacter</i> spp.. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 959-963.	1.3	23
292	<i>Editorial Commentary</i> : The New <i>Acinetobacter</i> Equation: Hypervirulence Plus Antibiotic Resistance Equals Big Trouble: Table 1.. <i>Clinical Infectious Diseases</i> , 2015, 61, 155-156.	2.9	23
293	Comparison of <i>Clostridium difficile</i> Ribotypes Circulating in Australian Hospitals and Communities. <i>Journal of Clinical Microbiology</i> , 2017, 55, 216-225.	1.8	23
294	Current evidence for therapy of ceftriaxone-resistant Gram-negative bacteremia. <i>Current Opinion in Infectious Diseases</i> , 2020, 33, 78-85.	1.3	23
295	Comprehensive analysis of IncC plasmid conjugation identifies a crucial role for the transcriptional regulator AcaB. <i>Nature Microbiology</i> , 2020, 5, 1340-1348.	5.9	23
296	<i>Simkania Negevensis</i> in Bronchoalveolar Lavage of Lung Transplant Recipients: A Possible Association with Acute Rejection. <i>Transplantation</i> , 2007, 83, 138-143.	0.5	22
297	Clinical and molecular correlates of virulence in <i>Escherichia coli</i> causing bloodstream infection following transrectal ultrasound-guided (TRUS) prostate biopsy. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2898-2906.	1.3	22
298	Species identification within <i>Acinetobacter calcoaceticus</i> “baumannii” complex using MALDI-TOF MS. <i>Journal of Microbiological Methods</i> , 2015, 118, 128-132.	0.7	22
299	Antecedent Carbapenem Exposure as a Risk Factor for Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae and Carbapenemase-Producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	22
300	Molecular Analysis of the Simultaneous Production of Two SHV-Type Extended-Spectrum Beta-Lactamases in a Clinical Isolate of <i>Enterobacter cloacae</i> by Using Single-Nucleotide Polymorphism Genotyping. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4716-4720.	1.4	21
301	Reducing the Development of Antibiotic Resistance in Critical Care Units. <i>Current Pharmaceutical Biotechnology</i> , 2011, 12, 2062-2069.	0.9	21
302	Replacement of healthcare-associated MRSA by community-associated MRSA in Queensland: Confirmation by genotyping. <i>Journal of Infection</i> , 2013, 67, 439-447.	1.7	21
303	Gram-negative resistance: can we combat the coming of a new “Red Plague”? <i>Medical Journal of Australia</i> , 2013, 198, 243-244.	0.8	21
304	A population-based spatio-temporal analysis of <i>Clostridium difficile</i> infection in Queensland, Australia over a 10-year period. <i>Journal of Infection</i> , 2014, 69, 447-455.	1.7	21
305	Comprehensive analysis of type 1 fimbriae regulation in <i>fimB</i> null strains from the multidrug resistant <i>Escherichia coli</i> ST131 clone. <i>Molecular Microbiology</i> , 2016, 101, 1069-1087.	1.2	21
306	Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against <i>Pseudomonas aeruginosa</i> for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	21

#	ARTICLE	IF	CITATIONS
307	Multidrug-Resistant Gram-Negative Pathogens: The Urgent Need for "Old" Polymyxins. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1145, 9-13.	0.8	21
308	Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	1.4	21
309	Cost-effectiveness of an Environmental Cleaning Bundle for Reducing Healthcare-associated Infections. <i>Clinical Infectious Diseases</i> , 2020, 70, 2461-2468.	2.9	21
310	KPC Type B-Lactamase, Rural Pennsylvania. <i>Emerging Infectious Diseases</i> , 2006, 12, 1613-1614.	2.0	20
311	Laboratory-based surveillance of <i>Clostridium difficile</i> circulating in Australia, September " November 2010. <i>Pathology</i> , 2016, 48, 257-260.	0.3	20
312	Is Ceftazidime/Avibactam an Option for Serious Infections Due to Extended-Spectrum- $\beta$ -Lactamase- and AmpC-Producing <i>Enterobacterales</i> ?: a Systematic Review and Meta-analysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	1.4	20
313	<i>Mycobacterium mucogenicum</i> Bacteremia in a Patient With Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 1998, 27, 346-347.	1.1	20
314	Has the Time Come for Routine Trimethoprim-Sulfamethoxazole Prophylaxis in Patients Taking Biologic Therapies?. <i>Clinical Infectious Diseases</i> , 2013, 56, 1621-1628.	2.9	19
315	Cytomegalovirus infections in lung and hematopoietic cell transplant recipients in the Organ Transplant Infection Prevention and Detection Study: A multi-year, multicenter prospective cohort study. <i>Transplant Infectious Disease</i> , 2018, 20, e12877.	0.7	19
316	Genomic analysis of carbapenemase-producing <i>Enterobacteriaceae</i> in Queensland reveals widespread transmission of bla <sub>IMP-4</sub> on an IncHI2 plasmid. <i>Microbial Genomics</i> , 2020, 6, .	1.0	19
317	Disseminated Donovanosis (Granuloma Inguinale) Causing Spinal Cord Compression: Case Report and Review of Donovanosis Involving Bone. <i>Clinical Infectious Diseases</i> , 1998, 26, 379-383.	2.9	18
318	Sequence type 131 fimH30 and fimH41 subclones amongst <i>Escherichia coli</i> isolates in Australia and New Zealand. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 351-358.	1.1	18
319	The use of SWATH to analyse the dynamic changes of bacterial proteome of carbapenemase-producing <i>Escherichia coli</i> under antibiotic pressure. <i>Scientific Reports</i> , 2018, 8, 3871.	1.6	18
320	How urgent is the need for new antifungals?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1857-1870.	0.9	18
321	Outbreaks of multidrug-resistant <i>Acinetobacter baumannii</i> strains in a Kenyan teaching hospital. <i>Journal of Global Antimicrobial Resistance</i> , 2014, 2, 190-193.	0.9	17
322	Variation in hospital cleaning practice and process in Australian hospitals: A structured mapping exercise. <i>Infection, Disease and Health</i> , 2017, 22, 195-202.	0.5	17
323	<i>Burkholderia pseudomallei</i> Clinical Isolates Are Highly Susceptible <i>In Vitro</i> to Cefiderocol, a Siderophore Cephalosporin. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	17
324	Emergence of bla <sub>OXA-181</sub> -carrying ColE plasmid in <i>Klebsiella pneumoniae</i> in Australia. <i>International Journal of Antimicrobial Agents</i> , 2013, 41, 294-296.	1.1	16

#	ARTICLE	IF	CITATIONS
325	Risk factors for urinary catheter associated bloodstream infection. <i>Journal of Infection</i> , 2015, 70, 585-591.	1.7	16
326	China's antibiotic resistance problems. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 351-352.	4.6	16
327	Novel Polymyxin Combination with the Antiretroviral Zidovudine Exerts Synergistic Killing against NDM-Producing Multidrug-Resistant <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	16
328	Incidence of community onset MRSA in Australia: least reported where it is Most prevalent. <i>Antimicrobial Resistance and Infection Control</i> , 2019, 8, 33.	1.5	16
329	Evaluation of Meropenem+Ciprofloxacin Combination Dosage Regimens for the Pharmacokinetics of Critically Ill Patients With Augmented Renal Clearance. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1104-1115.	2.3	16
330	Genetic Environment of 16S rRNA Methylase Gene <i>rmtD</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2270-2272.	1.4	15
331	Tuberculosis in the Australian Indigenous population: history, current situation and future challenges. <i>Australian and New Zealand Journal of Public Health</i> , 2011, 35, 6-9.	0.8	15
332	25-Hydroxyvitamin D Concentrations and <i>Clostridium difficile</i> Infection: A Meta-Analysis. <i>Journal of Parenteral and Enteral Nutrition</i> , 2017, 41, 890-895.	1.3	15
333	Peripherally InSerted CEntral catheter dressing and securement in patients with cancer: the PISCES trial. Protocol for a 2x2 factorial, superiority randomised controlled trial. <i>BMJ Open</i> , 2017, 7, e015291.	0.8	15
334	Serious Infections in the Intensive Care Unit: <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i> . <i>Clinical Infectious Diseases</i> , 2006, 43, S41-S42.	2.9	14
335	Pre-medication practices and incidence of infusion-related reactions in patients receiving AMPHOTECÂ®: data from the Patient Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability (PRoACT) registry. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1392-1400.	1.3	14
336	Transmission of Bacterial Infections to Healthcare Workers during Intubation and Respiratory Care of Patients with Severe Pneumonia. <i>Infection Control and Hospital Epidemiology</i> , 2009, 30, 1019-1021.	1.0	14
337	Determining research priorities for clinician-initiated trials in infectious diseases. <i>Medical Journal of Australia</i> , 2013, 198, 270-272.	0.8	14
338	Evaluation of the SpeeDx Carba (beta) multiplex real-time PCR assay for detection of NDM, KPC, OXA-48-like, IMP-4-like and VIM carbapenemase genes. <i>BMC Infectious Diseases</i> , 2019, 19, 571.	1.3	14
339	Culture-independent detection of chlorhexidine resistance genes <i>qacA/B</i> and <i>smr</i> in bacterial DNA recovered from body sites treated with chlorhexidine-containing dressings. <i>Journal of Medical Microbiology</i> , 2017, 66, 447-453.	0.7	14
340	Plasmid-Mediated Ciprofloxacin Resistance Imparts a Selective Advantage on <i>Escherichia coli</i> ST131. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0214621.	1.4	14
341	16S ribosomal RNA methylase <i>RmtD</i> produced by <i>Klebsiella pneumoniae</i> in Brazil. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 746-747.	1.3	13
342	PME-1-Producing <i>Pseudomonas aeruginosa</i> in Qatar. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3692-3693.	1.4	13

#	ARTICLE	IF	CITATIONS
343	Adverse clinical outcomes associated with infections by Enterobacterales producing ESBL (ESBL-E): a systematic review and meta-analysis. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, .	0.9	13
344	Rapid detection of NDM and VIM carbapenemase encoding genes by recombinase polymerase amplification and lateral flowâ€”based detection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 2447-2453.	1.3	12
345	Short- versus standard-course intravenous antibiotics for peri-prosthetic joint infections managed with debridement and implant retention: a randomised pilot trial using a desirability of outcome ranking (DOOR) endpoint. <i>International Journal of Antimicrobial Agents</i> , 2022, 60, 106598.	1.1	12
346	Exacerbated Hyperglycemia Associated with Nelfinavir. <i>Annals of Pharmacotherapy</i> , 1998, 32, 609-610.	0.9	11
347	Skin colonization at peripheral intravenous catheter insertion sites increases the risk of catheter colonization and infection. <i>American Journal of Infection Control</i> , 2019, 47, 1484-1488.	1.1	11
348	Sequential, Multiple-Assignment, Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART-COMPASS). <i>Clinical Infectious Diseases</i> , 2019, 68, 1961-1967.	2.9	11
349	Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales (â€œMERINO-3â€œ): study protocol for a multicentre, open-label randomised non-inferiority trial. <i>Trials</i> , 2021, 22, 301.	0.7	11
350	Combination therapy for bloodstream infections with carbapenemase-producing Enterobacteriaceae â€œ Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 1020-1021.	4.6	10
351	Clinical and Economic Outcomes of Genome Sequencing Availability on Containing a Hospital Outbreak of Resistant <i>Escherichia coli</i> in Australia. <i>Value in Health</i> , 2020, 23, 994-1002.	0.1	10
352	Transcriptomic responses of a New Delhi metallo-Î²-lactamase-producing <i>Klebsiella pneumoniae</i> isolate to the combination of polymyxin B and chloramphenicol. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106061.	1.1	10
353	A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent Î²-lactam antibiotic infusion in critically ill patients with sepsis: BLING III. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2019, 21, 63-68.	0.0	10
354	<i>Morganella morganii</i> , an Emerging Cause of Bloodstream Infections. <i>Microbiology Spectrum</i> , 2022, 10, e0056922.	1.2	10
355	Carriage Duration and Household Transmission of Enterobacterales Producing Extended-Spectrum Beta-Lactamase in the Community: A Systematic Review and Meta-Analysis. <i>Microbial Drug Resistance</i> , 2022, 28, 795-805.	0.9	10
356	Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2522-2531.	1.3	10
357	Antibiotic-resistant infections in the critically ill adult. <i>Clinics in Laboratory Medicine</i> , 2004, 24, 329-341.	0.7	9
358	An UHPLCâ€”MS/MS method for the simultaneous determination of ampicillin and sulbactam in human plasma and urine. <i>Bioanalysis</i> , 2015, 7, 2311-2319.	0.6	9
359	Outcomes with Cefiderocol Treatment in Patients with Bacteraemia Enrolled into Prospective Phase 2 and Phase 3 Randomised Clinical Studies. <i>Infectious Diseases and Therapy</i> , 2022, 11, 853-870.	1.8	9
360	More Evidence of the Benefits of Rational Antimicrobial Use in Clinical Practice. <i>Infection Control and Hospital Epidemiology</i> , 2003, 24, 642-643.	1.0	8



#	ARTICLE	IF	CITATIONS
361	<i>In situ</i> probing the interior of single bacterial cells at nanometer scale. <i>Nanotechnology</i> , 2014, 25, 415101.	1.3	8
362	The Use of Therapeutic Drug Monitoring to Optimize Treatment of Carbapenem-Resistant <i>Enterobacter</i> Osteomyelitis. <i>Microbial Drug Resistance</i> , 2015, 21, 631-635.	0.9	8
363	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 664-672.	1.1	8
364	Molecular epidemiology of <i>Pseudomonas aeruginosa</i> bloodstream infection isolates in a non-outbreak setting. <i>Journal of Medical Microbiology</i> , 2017, 66, 154-159.	0.7	8
365	Molecular Comparison of Bacterial Communities on Peripheral Intravenous Catheters and Matched Skin Swabs. <i>PLoS ONE</i> , 2016, 11, e0146354.	1.1	8
366	Could a herpesvirus mimic tacrolimus-induced leukoencephalopathy?. <i>Annals of Neurology</i> , 1997, 42, 270-270.	2.8	7
367	Active surveillance for multidrug-resistant Gram-negative bacteria in the intensive care unit. <i>Pathology</i> , 2015, 47, 575-579.	0.3	7
368	Differentiation of <i>Acinetobacter</i> Genomic Species 13BJ/14TU from <i>Acinetobacter haemolyticus</i> by Use of Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry (MALDI-TOF MS): TABLE 1. <i>Journal of Clinical Microbiology</i> , 2015, 53, 3384-3386.	1.8	7
369	Combination antibiotic therapy for <i>Pseudomonas aeruginosa</i> bacteremia in febrile neutropenic patients? The question still remains. <i>Infectious Diseases</i> , 2018, 50, 403-406.	1.4	7
370	Diagnosis of urinary tract infection in older persons in the emergency department: To pee or not to pee, that is the question. <i>EMA - Emergency Medicine Australasia</i> , 2019, 31, 856-862.	0.5	7
371	Optimal Therapy for Multidrug-Resistant <i>Acinetobacter baumannii</i> . <i>Emerging Infectious Diseases</i> , 2010, 16, 171-171.	2.0	6
372	Number of missed doses. <i>Aids</i> , 2012, 26, 1437-1440.	1.0	6
373	Infections Due to Other Members of the Enterobacteriaceae, Including Management of Multidrug-Resistant Strains. , 2012, , 1874-1877.		6
374	A hierarchical spatial modelling approach to investigate MRSA transmission in a tertiary hospital. <i>BMC Infectious Diseases</i> , 2013, 13, 449.	1.3	6
375	Rectal colonization with New Delhi metallo- $\beta$ -lactamase-1-producing <i>Escherichia coli</i> prior to transrectal ultrasound (TRUS)-guided prostate biopsy. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2957-2959.	1.3	6
376	Community-Acquired <i>Clostridium difficile</i> Infection, Queensland, Australia. <i>Emerging Infectious Diseases</i> , 2016, 22, 1659-1661.	2.0	6
377	Detection of carbapenemase activity in Enterobacteriaceae using LC-MS/MS in comparison with the neo-rapid CARB kit using direct visual assessment and colorimetry. <i>Journal of Microbiological Methods</i> , 2016, 131, 68-72.	0.7	6
378	General Practitioner Antimicrobial Stewardship Programme Study (GAPS): protocol for a cluster randomised controlled trial. <i>BMC Family Practice</i> , 2016, 17, 48.	2.9	6



#	ARTICLE	IF	CITATIONS
379	Antibiotics for Ceftriaxone Resistant Gram-Negative Bacterial Bloodstream Infectionsâ€”Reply. JAMA - Journal of the American Medical Association, 2019, 321, 613.	3.8	6
380	Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial. Trials, 2021, 22, 889.	0.7	6
381	Pasteurella species bloodstream infections in Queensland, Australia, 2000â€“2019. European Journal of Clinical Microbiology and Infectious Diseases, 2022, 41, 609.	1.3	6
382	Surveillance snapshot of Clostridium difficile infection in hospitals across Queensland detects binary toxin producing ribotype UK 244. Communicable Diseases Intelligence, 2014, 38, E279-84.	0.5	6
383	Sphingomonas paucimobilis bloodstream infection is a predominantly community-onset disease with significant lethality. International Journal of Infectious Diseases, 2022, 119, 172-177.	1.5	6
384	Cryptococcus neoformans infection. Liver Transplantation, 2002, 8, 846-847.	1.3	5
385	Mechanisms of Resistance of Bacteria Causing Ventilator-Associated Pneumonia. Clinics in Chest Medicine, 2005, 26, 75-79.	0.8	5
386	Appropriate Pharmacokinetic Index for Outcome in Staphylococcus aureus Pneumonia. Chest, 2007, 132, 1101-1102.	0.4	5
387	Cefepime MIC Breakpoint Resettlement in Gram-Negative Bacteria. Antimicrobial Agents and Chemotherapy, 2009, 53, 337-338.	1.4	5
388	Clearance of intravenous 5-fluorocytosine during continuous venovenous haemodiafiltration in a patient with hepatosplenic candidiasis. International Journal of Antimicrobial Agents, 2009, 34, 383-384.	1.1	5
389	Nanoscale Focused Ion Beam Tomography of Single Bacterial Cells for Assessment of Antibiotic Effects. Microscopy and Microanalysis, 2014, 20, 537-547.	0.2	5
390	Predictors of use of infection control precautions for multiresistant gram-negative bacilli in Australian hospitals: Analysis of a national survey. American Journal of Infection Control, 2014, 42, 963-969.	1.1	5
391	Draft Genome Sequences of Two IMP-4-Producing Escherichia coli Sequence Type 131 Isolates in Australia. Genome Announcements, 2015, 3, .	0.8	5
392	Local acquisition and nosocomial transmission of Klebsiella pneumoniae harbouring the blaNDMâ€” gene in Australia. Medical Journal of Australia, 2015, 202, 270-271.	0.8	5
393	Evaluation of phenotypic screening tests for carbapenemase production in Pseudomonas aeruginosa from patients with cystic fibrosis. Journal of Microbiological Methods, 2015, 111, 105-107.	0.7	5
394	Fosfomycin: what was old is new again. Internal Medicine Journal, 2018, 48, 1425-1429.	0.5	5
395	The risk of resistance: what are the major antimicrobial resistance threats facing Australia?. Medical Journal of Australia, 2019, 211, 103.	0.8	5
396	<i>In Vitro</i> Activity of Cefotetan against ESBL-Producing Escherichia coli and Klebsiella pneumoniae Bloodstream Isolates from the MERINO Trial. Microbiology Spectrum, 2021, 9, e0022621.	1.2	5

#	ARTICLE	IF	CITATIONS
397	Modifying Antibiotic Prescribing in Primary Care. <i>Clinical Infectious Diseases</i> , 2006, 42, 1231-1233.	2.9	4
398	A multilevel model of methicillin-resistant <i>Staphylococcus aureus</i> acquisition within the hierarchy of an Australian tertiary hospital. <i>American Journal of Infection Control</i> , 2012, 40, 787-793.	1.1	4
399	The Challenge of Treating Superbugs. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015, 36, 001-002.	0.8	4
400	Re-activation of varicella zoster virus associated with anterior spinal cord stroke in pregnancy. <i>Infectious Diseases</i> , 2016, 48, 705-707.	1.4	4
401	Reply to Corona and Cattaneo. <i>Clinical Infectious Diseases</i> , 2017, 65, 870-871.	2.9	4
402	Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against <i>Pseudomonas aeruginosa</i> and <i>Escherichia coli</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 91, 69-76.	0.8	4
403	OUP accepted manuscript. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab157.	0.9	4
404	Evaluation of quick sequential organ failure assessment and systemic inflammatory response syndrome in patients with gram negative bloodstream infection. <i>Infection, Disease and Health</i> , 2020, 25, 151-157.	0.5	4
405	Activity of temocillin against third-generation cephalosporin-resistant <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> bloodstream isolates from a clinical trial. <i>JAC-Antimicrobial Resistance</i> , 2022, 4, dlab192.	0.9	4
406	Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against <i>Pseudomonas aeruginosa</i> Bacteremia in the Hollow-Fiber Infection Model. <i>Microbiology Spectrum</i> , 2022, 10, e0052522.	1.2	4
407	The molecular epidemiology of extended-spectrum beta-lactamase producing organisms. <i>Enfermedades Infecciosas Y MicrobiologAa Clnica</i> , 2008, 26, 403.	0.3	3
408	<i>Klebsiella pneumoniae</i> Carbapenemase-Producing Enterobacteriaceae, Northeast Florida. <i>Southern Medical Journal</i> , 2009, 102, 680-687.	0.3	3
409	Bacterial identification using a SCIEX 5800 TOF/TOF MALDI research instrument and an external database. <i>Journal of Microbiological Methods</i> , 2019, 164, 105685.	0.7	3
410	Long term sepsis readmission, mortality and cause of death following Gram negative bloodstream infection: a propensity matched observational linkage study. <i>International Journal of Infectious Diseases</i> , 2022, 114, 34-44.	1.5	3
411	Effect of a Selective Decontamination of the Digestive Tract Regimen Including Parenteral Cefepime on Establishment of Intestinal Colonization with Vancomycin-Resistant <i>Enterococcus</i> spp. and <i>Klebsiella pneumoniae</i> in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 2537-2540.	1.4	2
412	Doubtful Model Utility in Predicting High Vancomycin Minimum Inhibitory Concentration Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream Infection Episodes. <i>Clinical Infectious Diseases</i> , 2011, 53, 1166-1167.	2.9	2
413	Predominance of VREfm ST203 subgroup in Queensland. <i>Pathology</i> , 2013, 45, 99.	0.3	2
414	Completing the Picture—Capturing the Resistome in Antibiotic Clinical Trials. <i>Clinical Infectious Diseases</i> , 2021, 72, e1122-e1129.	2.9	2

#	ARTICLE	IF	CITATIONS
415	Population Pharmacokinetics Analysis of Amikacin Initial Dosing Regimen in Elderly Patients. <i>Antibiotics</i> , 2021, 10, 100.	1.5	2
416	The Epidemiology of Pan/Extreme Drug Resistance. , 2012, , 27-38.		2
417	An update on cefepime and its future role in combination with novel $\beta$ -lactamase inhibitors for MDR Enterobacterales and <i>Pseudomonas aeruginosa</i> response. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3327-3328.	1.3	2
418	<i>Clostridium Difficile</i> Diarrhoea Associated with Chemotherapy for Ovarian Cancer. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 1997, 37, 348-349.	0.4	1
419	Modern Clinician-initiated Clinical Trials to Determine Optimal Therapy for Multidrug-resistant Gram-negative Infections. <i>Clinical Infectious Diseases</i> , 2020, 71, 433-439.	2.9	1
420	Letter From Australia: A Never-Ending Pandemic?. <i>Annals of Internal Medicine</i> , 2021, , .	2.0	1
421	Cellulitis caused by a multidrug-resistant group A streptococcus. <i>Medical Journal of Australia</i> , 1996, 165, 61-62.	0.8	0
422	Infections with Organisms Producing Extended-Spectrum $\beta$ -Lactamase. <i>Issues in Infectious Diseases</i> , 2010, , 21-34.	0.1	0
423	Reply to Soman et al. <i>Clinical Infectious Diseases</i> , 2013, 57, 323-324.	2.9	0
424	Reply to Bonten and Mevius. <i>Clinical Infectious Diseases</i> , 2015, 60, 1867-1868.	2.9	0
425	Reply to Reza Hosseini and Nielsen. <i>Clinical Infectious Diseases</i> , 2021, 72, e916-e916.	2.9	0
426	Global Spread of Multidrug-Resistant Gram-Negative Bacilli. , 0, , 213-222.		0
427	Determining risk factors for symptomatic urinary tract infection following trial of void: A retrospective analysis. <i>Journal of Clinical Urology</i> , 0, , 205141582210998.	0.1	0